Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS.

Sequential serum samples from 13 homosexual men who seroconverted for antibodies to human immunodeficiency virus (HIV) were tested for HIV antigen. In one of these men, who developed the acquired immune deficiency syndrome (AIDS), HIV antigenaemia preceded the onset of AIDS by more than a year and persisted throughout the course of the disease. This antigenaemia was accompanied by the disappearance of IgG antibody reactivity to the major HIV core protein p24. In none of the 12 others, who all remained without serious disease, were serum concentrations of HIV antigen detected, except on one occasion in one man. All their serum samples showed strong IgG antibody reactivity to p24. Nine children who were infected with HIV in 1981 by plasma transfusion from a single donor were also followed up for HIV antigenaemia. HIV antigen was almost constantly present in the serum (26 of 28 samples) of five children who developed AIDS related complex or AIDS and less often in the serum (four of 10 samples) of four children who remained free of symptoms. The two children who developed AIDS showed a virtual absence of antibody reactivity to p24. These results indicate that increased HIV gene expression is a contributing factor to the development of AIDS and also provide evidence for a switch from latent to active HIV infection.

[1]  J. Allan,et al.  Antigens of Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus , 1986 .

[2]  L. Epstein,et al.  EXPRESSION OF HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN (HIV-Ag) IN SERUM AND CEREBROSPINAL FLUID DURING ACUTE AND CHRONIC INFECTION , 1986, The Lancet.

[3]  W. Kuis,et al.  HTLV-III/LAV infection in nine children infected by a single plasma donor: clinical outcome and recognition patterns of viral proteins. , 1986, The Journal of infectious diseases.

[4]  J Coffin,et al.  What to call the AIDS virus? , 1986, Nature.

[5]  R. Zaizov,et al.  Viral envelope protein of HTLV-III is the major target antigen for antibodies in hemophiliac patients. , 1986, The Journal of infectious diseases.

[6]  K. Steimer,et al.  Recombinant polypeptide from the endonuclease region of the acquired immune deficiency syndrome retrovirus polymerase (pol) gene detects serum antibodies in most infected individuals , 1986, Journal of virology.

[7]  J. Goedert,et al.  Long-term seropositivity for human T-lymphotropic virus type III in homosexual men without the acquired immunodeficiency syndrome: development of immunologic and clinical abnormalities. A longitudinal study. , 1986, Annals of internal medicine.

[8]  T. Copeland,et al.  Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. , 1986, Science.

[9]  Susan E. Wilson,et al.  Three-year incidence of AIDS in five cohorts of HTLV-III-infected risk group members. , 1986, Science.

[10]  A. Fauci,et al.  Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency. , 1986, Science.

[11]  J. Goudsmit,et al.  Introduction of lymphadenopathy associated virus or human T lymphotropic virus (LAV/HTLV-III) into the male homosexual community in Amsterdam. , 1986, Genitourinary medicine.

[12]  J. Goudsmit,et al.  Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus. , 1986, British medical journal.

[13]  R. Schooley,et al.  Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. , 1985, The New England journal of medicine.

[14]  K. Steimer,et al.  Infection by the retrovirus associated with the acquired immunodeficiency syndrome. Clinical, biological, and molecular features. , 1985, Annals of internal medicine.

[15]  R. Gallo,et al.  Human T-lymphotropic retroviruses , 1985, Nature.

[16]  J. Groopman,et al.  Antibody seronegative human T-lymphotropic virus type III (HTLV-III)-infected patients with acquired immunodeficiency syndrome or related disorders. , 1985, Blood.

[17]  S. Devare,et al.  Human T-cell lymphotropic virus type III: immunologic characterization and primary structure analysis of the major internal protein, p24 , 1985, Journal of virology.

[18]  J. Groopman,et al.  Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. , 1985, Science.

[19]  H. Joller,et al.  Antibodies to HTLV-III in Swiss patients with AIDS and pre-AIDS and in groups at risk for AIDS. , 1985, The New England journal of medicine.

[20]  J. Curran,et al.  The incidence rate of acquired immunodeficiency syndrome in selected populations. , 1985, JAMA.

[21]  J. Chermann,et al.  Antibodies to the core protein of lymphadenopathy-associated virus (LAV) in patients with AIDS. , 1984, Science.

[22]  R. Coutinho,et al.  Efficacy of a heat inactivated hepatitis B vaccine in male homosexuals: outcome of a placebo controlled double blind trial. , 1983, British medical journal.

[23]  F. Greenwood,et al.  Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity , 1962, Nature.